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We estimated cost-effectiveness of annually vaccinat-
ing children not at high risk with inactivated influenza vac-
cine (IIV) to range from US $12,000 per quality-adjusted life
year (QALY) saved for children ages 6–23 months to
$119,000 per QALY saved for children ages 12–17 years.
For children at high risk (preexisting medical conditions)
ages 6–35 months, vaccination with IIV was cost saving.
For children at high risk ages 3–17 years, vaccination cost
$1,000–$10,000 per QALY. Among children not at high risk
ages 5–17 years, live, attenuated influenza vaccine had a
similar cost-effectiveness as IIV. Risk status was more
important than age in determining the economic effects of
annual vaccination, and vaccination was less cost-effective
as the child’s age increased. Thus, routine vaccination of all
children is likely less cost-effective than vaccination of all
children ages 6–23 months plus all other children at high
risk.
T
he risks of influenza, both annual epidemic and pan-
demic, have caused national policymakers to ask
whether routine influenza vaccination should be expanded
to healthy children and adults of all ages. During the
2003–04 influenza season, reports of >150 influenza-asso-
ciated deaths among children and unprecedented demand
for influenza vaccine highlighted the need to reevaluate the
nation’s influenza vaccination policies regarding children
(1–3). The Advisory Committee on Immunization
Practices (ACIP) and the American Academy of Pediatrics
Red Book Committee have recommended that all children
6–23 months of age and their household contacts should
receive annual influenza vaccination, and this policy has
been widely adopted (4,5). In February 2006, the ACIP
recommended expanding routine influenza vaccination to
children 24–59 months old (L. Pickering, pers. comm.).
However, a vote to recommend routine influenza vaccina-
tion for all children and adults failed. ACIP members
requested more information on the projected health bene-
fits, cost-effectiveness, and logistical issues regarding
expanding influenza recommendations to other age
groups.
Should influenza vaccine be routinely used in older
children without high-risk conditions? This question is
especially relevant, given the introduction of live, attenu-
ated (intranasal) influenza vaccine (LAIV) for healthy per-
sons ages 5–49 years, which has a higher list price than the
inactivated (injected) vaccine but is also potentially more
effective (6,7). Previous studies have examined the cost-
effectiveness of influenza vaccination in various age
groups (8–10). However, these studies may have been
overly optimistic regarding vaccination because they
assumed high influenza attack rates, low estimates for vac-
cination costs, or both, thereby limiting their use in policy
decisions. Further, no studies have been published that
compare the cost-effectiveness of live attenuated influenza
vaccines with that of inactivated influenza vaccines.
Our objective in this study was to evaluate the cost-
effectiveness of routine annual influenza vaccination,
comparing live attenuated with inactivated vaccines, for
children in varying age and risk groups from 6 months to
17 years. This is the first study to include measures of
health preferences that allow results to be calculated in
quality-adjusted life years (QALYs).
Methods
Using standard software (TreeAge Pro 2004 Software,
release 6, Treeage Software, Williamstown, MA, USA),
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§Children’s Hospital, Boston, Massachusetts, USAwe created a mathematical model (decision tree) to esti-
mate the effect of influenza vaccination on outcomes and
costs among children. The decision tree evaluated 3
options: 1) no vaccination; 2) inactivated influenza vaccine
(IIV); and 3) live, attenuated influenza vaccine (LAIV). It
estimated costs and outcomes for influenza-related illness
for children stratified into 10 subgroups by age (6–23
months, 2 years [24–35 months], 3–4 years, 5–11 years,
12–17 years) and risk status (high risk or not at high risk).
Children were defined as being at high risk for influenza-
related complications due to preexisting medical condi-
tions (4). Since most costs and consequences related to
influenza occur during a single influenza season, the time
horizon of the decision tree was 1 year. Costs and effects of
long-term outcomes (death, long-term sequelae of influen-
za-related hospitalization or vaccine adverse events), how-
ever, were also included in the model. A simplified
schematic of the decision tree is shown in Figure 1. Input
parameters for probabilities, costs, and outcomes were
described by using probability distributions (Tables 1–3).
Natural History of Influenza
Influenza-related outcomes included in the decision
tree were episodes of influenza illness (medically attend-
ed or not), otitis media, mild pneumonia (and other com-
plications treated on an outpatient basis), hospitalizations
(with and without long term sequelae), and deaths. Event
rates, by age and risk group, were derived from the pub-
lished literature and were supplemented by expert opinion
where data were limited or unavailable (Table 1) (11–15)
(see Online Appendix for full list of references; available
from http://www.cdc.gov/ncidod/eid/vol12no10/05-1015.
htm).
Vaccine Effectiveness
Inactivated vaccine was considered for all 10 sub-
groups, and LAIV was considered only for children not at
high risk. Children 6 months to 4 years were included as a
theoretical intended population for LAIV, although LAIV
is currently licensed in the United States only for children
5–17 years. The most likely estimate for vaccine effective-
ness against symptomatic influenza illness was lower for
IIV (0.690) than the most likely estimate for LAIV (0.838)
(Table 1) (16,17). 
Vaccination-related Adverse Events
Adverse events attributable to influenza vaccination
included in the decision tree were medically-attended
episodes of injection site reactions, systemic reactions
(defined as fever within 2–7 days of vaccination), anaphy-
laxis, and Guillain-Barré syndrome (Table 1). Probabilities
of medically-attended vaccine adverse events were highest
for the youngest age group and declined as age increased.
Costs
Costs included direct medical costs (physician visits,
over-the-counter remedies, prescription drugs, diagnostic
tests, and hospitalizations) and opportunity costs (parent
time costs) for physician visits (Table 2). All costs were
adjusted to 2003 dollars by using the medical cost compo-
nent of the Consumer Price Index (available from
http://data.bls.cgi-bin/surveymost?cu). Costs of physician
visits for influenza illness, influenza-related hospitaliza-
tions, and vaccination-related adverse events were calcu-
lated by using a large database that reported payments for
health insurance companies in the mid-Atlantic states of
the United States (The Medstat Group, Ann Arbor, MI,
USA). Vaccination costs included vaccine dose costs,
administration costs, medical attention for vaccine adverse
events, and, if an additional visit was required, parent time
costs (18,19).
It is recommended that first-time recipients aged 6
months through 8 years receive 2 doses of influenza vac-
cine (4). Some children will also require additional office
visits to be vaccinated with either 1 or 2 doses. The mean
number of additional office visits needed to deliver the rec-
ommended number of doses ranged from 1.07 for children
ages 6–23 months to 0.75 for children ages 5–17 years
(Table 2) (20).
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Figure 1. Influenza cost-effectiveness model. Each health state in
the model is associated with a cost and quality adjustment from
Table 1. RESEARCH
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The model projected 4 different outcomes that were
averted through vaccination: influenza episodes, hospital-
izations, deaths, and QALYs. The QALY is a measure of
net health effects that takes into account the health benefits
of averted influenza cases as well as the health costs of
vaccination-related adverse events. We obtained QALY
valuations for each health event in the model from 2 stud-
ies (Table 3) (21,22). In these studies, adult respondents
were asked for the amount of time that they were willing
to give up from the end of their life to prevent a specific
temporary health state in a hypothetical child. We explicit-
ly asked respondents to include a parent’s reduction in
quality of life associated with a child’s illness and any time
lost from work to care for a sick child in the time-tradeoff
valuation; therefore, time-tradeoff amounts could exceed
the length of the event. QALYs lost due to severely dis-
abling long-term sequelae after influenza hospitalization,
such as acute necrotizing encephalopathy with irreversible
neurologic damage, were also included (23,24). An
influenza-related death was assumed to result in the loss of
1 QALY for each year of life lost.
Analysis Plan
The primary outcome measure was the incremental
cost-effectiveness ratio in dollars per QALY. Secondary
measures included costs and events averted per 1,000 vac-
cinated children, dollars per influenza-related event avoid-
ed, dollars per hospitalization avoided, and dollars per
death averted. One-way sensitivity analyses were conduct-
ed on all variables, in which the impact on the average
$/QALY saved was examined by altering each variable
Influenza Vaccination of Children
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sitivity analyses were conducted on variables for which the
results were most sensitive in 1-way sensitivity analysis. A
scenario analysis examined the effect of excluding parent
time costs. Another scenario analysis evaluated the effect
of using an alternative calculation for quality adjustments,
which used the duration of the health state in the child as
the denominator instead of respondent’s life expectancy.
To evaluate the effects of parameter uncertainty, a proba-
bilistic sensitivity analysis was conducted. For the proba-
bilistic sensitivity analysis, each variable was assigned a
distribution of possible values, assuming β distributions
for probabilities and quality adjustments and log-normal
distributions for costs (a technical appendix listing details
of all distributions is available online at http://www.
cdc.gov/ncidod/eid/vol12no10/05-1015.htm). For each run
in the probabilistic sensitivity analysis, the model random-
ly picked a different value for each variable from its asso-
ciated distribution. The model was run 10,000 times for
each age-risk and vaccine combination separately. Cost-
effectiveness acceptability curves show the cumulative
probabilities of the cost-effectiveness ratio, from $0 to
$250,000/QALY, due to vaccinating children against
influenza (i.e., the curves display the probability of the
cost-effectiveness being less than or equal to a given
$/QALY amount), by using the results from the Monte
Carlo analysis.
Results
Health Benefits, Risks, and Costs
Influenza vaccination with IIV was projected to be cost
saving for children ages 6–35 months at high risk and to
require a net investment for all other age and risk groups.
The projected benefits of vaccination decreased as age
increased (Table 4). For example, routine influenza vacci-
nation with IIV of children 6–23 months old not at high
risk was projected to avert 108 influenza events per 1,000,
while vaccination of 5- to 11-year-old children was pro-
jected to averted 55 influenza events per 1,000. Among the
5- to 11-year-olds not at high risk, the projected number of
influenza-related hospitalizations and deaths averted by
influenza vaccination with IIV was only one tenth the
number averted among 6- to 23-month-old children not at
high risk. For children not at high-risk age >5 years, the
number of projected influenza events averted was similar
for LAIV and IIV.
QALYs and Cost-Effectiveness
All vaccination strategies had net positive QALYs
gained, which indicated that the health benefits of vaccina-
tion outweighed the risks (Table 4). For children not at-
high risk, the QALYs gained by IIV use were highest for 6-
to 23-month-olds at 3.0 QALYs gained per 1,000 children
vaccinated, compared with 2.4 per 1,000 children vaccinat-
ed for 2-year-olds and 1.7 per 1,000 children vaccinated for
3- to 4-year-olds. For children at high risk, the QALYs
gained by IIV use ranged from 1.3 to 7.2 per 1,000 children
vaccinated, depending on age group. For children 5–17
years old not at high risk, LAIV use would result in slight-
ly higher QALYs gained because of the vaccine’s higher
effectiveness at 0.5 to 3.7 per 1,000 children vaccinated.
IIV use was cost saving among children at high risk
ages 6 months to 2 years (Table 5). For children <5 years
not at high risk as well as children at high risk in all age
groups, IIV use had mean cost-effectiveness ratios of
<$30,000 per QALYsaved. Cost-effectiveness ratios based
on dollars per influenza episode averted yielded patterns
similar to the ratios of dollars per QALY saved, ranging
from cost savings for children at high risk ages <2 years to
$1,070 per influenza case averted for healthy 12- to 17-
year-olds (Table 5).
Using base-case vaccine purchase prices for LAIV and
IIV (Table 2), LAIV for children ages 5–17 years not at
high risk had higher mean net costs and yielded greater
mean health benefits than IIV. The cost-effectiveness ratios
for LAIV were $72,000 per QALY gained for 5- to 11-
year-olds and $109,000 per QALY gained for 12- to 17-
year-olds (Table 5).
Sensitivity Analyses
Probabilistic sensitivity analysis provided confidence
intervals for projected costs and events averted and quasi-
confidence intervals for cost-effectiveness ratios. By using
RESEARCH
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favorable than IIV (compared to no vaccination), and
vaccination with LAIV is the preferred strategy. However,
probabilistic sensitivity analysis indicated projected results
were similar for IIV and LAIV.
Cost-effectiveness acceptability curves generated
through probabilistic sensitivity analysis are very similar
for IIV and LAIV (Figures 2A and 2C). The probability
that the cost-effectiveness of IIV would be
<$30,000/QALY ranged from 51% to 89% for all children
ages 6–23 months and 2 years (Figure 2). For children of
any age not at high risk, the probability that IIV would be
cost saving was <10% (Figure 2A). For children aged >5
years not at high risk, the probability that the cost-effec-
tiveness of LAIV, compared with no vaccination, would be
<$30,000 per QALY gained was 5%–13% (Figure 2C).
In 1-way sensitivity analyses, cost-effectiveness ratios
were most sensitive to changes in influenza illness attack
rate, hospitalization rates, total vaccination costs, and vac-
cine effectiveness (Figure 3). Cost-effectiveness ratios var-
ied notably with total costs of vaccination for IIV. For
example, if total costs of vaccination were doubled for
children ages 6–23 months who were not at high risk, cost-
effectiveness ratios increased (worsened) by a factor of 3.
We included costs for parent time associated with taking a
child to the physician’s office to receive influenza vaccina-
tion, which accounted for 41%–66% of total vaccination
costs (Table 1). Excluding these time costs resulted in cost-
effectiveness ratios approximately half of those reported in
Table 5 and Figure 2. Using an alternative calculation for
quality adjustments resulted in higher estimates of the pro-
jected number of QALYs gained through vaccination. For
Influenza Vaccination of Children
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example, projected gains in QALYs for children not at
high risk were 12%–37% higher than in the base case.
Two-way sensitivity analysis on influenza illness rate
and vaccine effectiveness (IIV) resulted in changes in the
cost-effectiveness ratio from a decrease in 11% for a sea-
son with a high influenza illness rate (35%) and high vac-
cine effectiveness (IIV) to an increase of more than a
factor of 30 for seasons with a low influenza illness rate
and low vaccine effectiveness (IIV). Combining a high
influenza illness rate (35%) with low vaccine effectiveness
(IIV) resulted in cost-effectiveness ratio ≈3 times base case
results ($43,000/QALY) for children not at high risk ages
6–23 months. Two-way sensitivity analyses on influenza
illness rate and total vaccination costs (IIV) had similar
results, ranging from a decrease in 6% in the cost-effec-
tiveness ratio to an increase 25 times as high as the base
case for seasons with low influenza illness rate and high
vaccination costs (IIV). Two-way sensitivity analyses for
vaccination costs and effectiveness yielded a 20% lower
cost-effectiveness ratio for low costs and high effective-
ness of vaccination (IIV) to 7 times the base case for high
costs and low vaccine effectiveness (IIV).
Discussion
Major Findings
We found that influenza vaccination of children, both
those at high risk and those not at high risk, in all age
groups would have health benefits that outweigh vaccine
adverse events as measured by QALYs for both IIV and
LAIV. For children not at high risk ages 6 months–4 years,
we estimated that influenza vaccination with IIV would
cost <$25,000 per QALY saved. In comparison, other rou-
tinely-used preventive interventions, such as pneumococ-
cal conjugate vaccination, cost an average of
$7,000/QALYfor children <2 years (22,25); driver-side air
bags cost $30,000/QALY (26), and costs of other vaccina-
tions range from cost-savings to $150,000/QALY (27–30).
Live, attenuated influenza vaccine is currently
approved for children >5 years of age who are not at high
risk, but not for children <5 years or for children at high
risk. At a price per dose <$20, its cost-effectiveness ratios
are similar to those for IIV. This analysis likely presents a
relatively conservative estimate of the potential benefits of
LAIV, because we did not include its potentially greater
effectiveness against antigenically drifted strains or likely
higher effectiveness with 1 dose of vaccine in previously
unvaccinated children <9 years (4,6).
The sensitivity of the results to the influenza illness
attack rate (which varies from season to season and from
community to community) and to vaccine effectiveness
indicates that the cost-effectiveness of influenza vaccina-
tion can vary considerably from year to year. In seasons
with a low influenza attack rate, the cost-effectiveness of
vaccination with IIV would be dramatically higher than in
the base case (Figure 3). The 2-way sensitivity analysesdemonstrate even less favorable cost-effectiveness for a
scenario that assumes a low influenza illness rate and low
level of vaccine effectiveness. In addition, the sensitivity of
these results to the total costs of vaccination highlights the
potential for delivering vaccinations in settings that have
lower costs and reduce the time required for vaccination.
Comparisons with Previous Studies
Our study contributes valuable new information
because it incorporates survey-based health state prefer-
ences for influenza-related illness and vaccine adverse
events. These preferences, which are expressed as QALYs
saved, are important for 2 reasons. First, we were able to
evaluate the net health benefits of vaccination by subtract-
ing the QALYs lost due to vaccine adverse events from the
QALYs gained due to averted influenza cases. The results
suggest that vaccination of all children is desirable from a
health standpoint. Second, the outcome measure of dollars
per QALYsaved allows policymakers to compare the cost-
effectiveness of influenza vaccination of children with
other potential investments in preventive health services.
Authors of other economic analyses of influenza vacci-
nation in children concluded that vaccination was more
cost-effective than we found in our study (8,9,31).
However, in these studies, the authors either did not sepa-
rate children at high risk from those not at risk (31) or did
not allow for sufficient variability in key variables (8,9).
These studies assumed substantially higher influenza
attack rates (8,9), higher levels of vaccine effectiveness
(8,9), and lower total costs of vaccination (8–10), all of
which would favor vaccination. However, we believe that
it is more accurate to include variation in both incidence of
influenza-related clinical illnesses and rates of influenza-
related health outcomes. Neither our study nor the previ-
ous studies included potential benefits of herd immunity.
In a recent study that used cost-benefit analysis to eval-
uate the economics of influenza vaccination in children,
Meltzer et al. arrived at conclusions similar to this analysis
for many of the age/risk groups under consideration (32).
Meltzer et al. found that annual vaccination of children not
at high risk was unlikely to be cost-saving and that annual
vaccination of children 6–23 months at high risk was like-
ly to generate cost savings. For older children at high risk,
they estimated median cost savings, but this analysis proj-
ects net costs of influenza vaccination for similar-age risk
groups. 
Limitations
Some studies that used mathematical models have sug-
gested substantial community herd immunity effects from
vaccinating school-aged children (33). Although one study
demonstrated herd immunity with vaccination rates of
>80% among school-aged children during the 1968 pan-
demic (34), a recent study by Pisu et al. (35) reported that
vaccinating 20%–25% of children <5 years of age in a
Texan community did not generate any measurable herd
immunity in persons <35 years. Additionally, no field stud-
ies have assessed the impact of pediatric vaccination on
hospitalization and deaths in adults. Thus, we made the
conservative decision to not include herd immunity effects
in our analysis. If herd immunity effects had been included
in our analysis, the findings would likely have been more
favorable for vaccination. Future analyses should evaluate
the cost-effectiveness of expanding routine influenza
Influenza Vaccination of Children
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Figure 2. Cost-effectiveness acceptability curves for inactivated
influenza vaccine compared with no vaccination (A, children not a
high risk; B, children at high risk). Cost-effective acceptability
curves for live, attenuated vaccine compared with no vaccine (C,
children not at high risk only). Box indicates the mean cost-
effectiveness ratio.immunization under different assumptions for vaccine cov-
erage rates and the costs of achieving these rates.
A recent randomized trial suggests that influenza vacci-
nation has little, if any, effect on otitis media in children
(36), while previous trials have found that influenza vacci-
nation reduces otitis media (6,37). Our model assumes that
only a small proportion of otitis media is preventable by
influenza vaccination, and our findings are consistent with
estimates of otitis media reduction from influenza vaccina-
tion reported in all of these studies. Our model is conserva-
tive in that it only includes the effect of reduced incidence
of otitis media (or other complications) due to reduced inci-
dence of influenza illness and does not consider any other
benefits of vaccination, such as whether vaccinated patients
with influenza illness may have a lower probability of
experiencing otitis media (or other complications).
The time-tradeoff questions we used to elicit prefer-
ences for health states differ from that commonly used for
adult illnesses because the loss of quality of life for both
parent and child are explicitly included. In addition, par-
ents were asked to include the value of productivity losses
to paid or unpaid work for caring for a child with influen-
za in the time-tradeoff amount; therefore, productivity
losses were included in the health state quality adjust-
ments, whereas parent time costs for vaccination were
included as dollar costs. As a result, the time-tradeoff
amounts presented here are not directly comparable to util-
ity values from generic utility instruments for measuring
reductions in quality-of-life for chronic health states, such
as the Health Utilities Index (38) or the EQ-5D (39). The
sample sizes for the time-tradeoff studies were small.
Recent data show that some influenza-related deaths in
children may occur outside the medical setting (2). Only
deaths that occurred after an influenza-related hospitaliza-
tion have been included in this analysis. However, even a
10-fold increase in influenza-related deaths did not appre-
ciably change the cost-effectiveness results since the total
number of deaths remains small.
Few data are available to guide assumptions on what
proportion of children who experience mild systemic
symptoms after vaccination, such as fever or respiratory
symptoms, will see a physician. In the absence of reliable
data, we selected an assumption that would be more likely
to bias against vaccination rather than for and assumed it
would be the same as the proportion of children who
would visit a physician due to influenza illness. If the num-
ber of medically attended, vaccination-related adverse
events were lower, the cost-effectiveness ratios would also
be slightly lower, but cost-effectiveness results are not
very sensitive to this parameter. We did not include any
quality adjustment for vaccination itself aside from nega-
tive effects of vaccination-related adverse events. If vacci-
nation itself were associated with a decrease in quality of
life, cost-effectiveness ratios would be less favorable than
in the current analysis. Previous analyses of other vaccina-
tions, which included a quality adjustment for fever and
fussiness following vaccination, were not sensitive to this
parameter (22,40).
Conclusions
Routine annual influenza vaccination using IIV for
children age >2 years not at high risk is likely to result in
net health benefits, but cost-effectiveness ratios are likely
to be less favorable than for children ages 6–23 months
and children of any age with a high-risk condition. Cost-
effectiveness among children decreases with increasing
age, although risk status is more important than age in
determining the economic impact of annual influenza vac-
cination. Further work is needed to assess the potential
impact of herd immunity on the cost-effectiveness of
expanding influenza vaccine recommendations.
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